Compare Mesoblast Limited (MESO) vs Virgin Galactic Holdings, Inc. (SPCE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Virgin Galactic Holdings, Inc. — how do they compare? Mesoblast Limited trades at $16.25 (market cap $2.17B), while Virgin Galactic Holdings, Inc. trades at $2.68 (market cap $329.06M). The key difference: Mesoblast Limited is far larger — about 6.6× Virgin Galactic Holdings, Inc.'s market cap, and Mesoblast Limited is trading nearer its 52-week high, Virgin Galactic Holdings, Inc. nearer its low. Which is the better fit depends on your goals.
| MESO | SPCE | |
|---|---|---|
Market Cap | $2.17B | $329.06M |
Sector | Technology | Industrials |
52-Week High | $20.96 | $7.52 |
52-Week Low | $12.88 | $2.17 |
Enterprise Value | $2.17B | $428.90M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.
Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.
Virgin Galactic (SPCE) trades at $2.58, up 0.78% on the day, amid a bearish technical outlook and deeply negative profitability. The company continues to post significant losses, with a net income margin of -19,781.3% in 2025 and negative cash flow from operations. Recent news highlights volatility in the space sector, with SPCE shares reacting to broader industry movements and specific corporate actions like stock awards.
The outlook remains highly speculative, with substantial execution risks and cash burn posing challenges. Investment opportunity hinges on future commercialization success, but current fundamentals and analyst divergence suggest caution. Key risks include reliance on future funding and intense competition in the space tourism sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Virgin Galactic Holdings, Inc.
Virgin Galactic Holdings Inc. develops space vehicles. The Company designs exploration technology such as missiles, rockets, and other related equipment. Virgin Galactic Holdings serves customers in the United States.
Read more on SPCE →
